All In Biotech

Drug Trial Radar · NCT07676175

A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL)

An Open-Label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BEBT-908 Plus CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL), and to Explore the Relationship Between Tumor Biomarkers and the Efficacy and Safety of BEBT-908 Plus CHOP.

Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jul 1, 2026

Primary completion

Jan 31, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
BeBetter Med IncIndustry
Sponsor type
Industry
Collaborators
Sun Yat-Sen University Cancer Center; First Affiliated Hospital Xi'an Jiaotong University
First posted
Jun 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to find the best way to combine the study drug BEBT-908 (ifupinostat hydrochloride for injection) with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) for treating previously untreated peripheral T-cell lymphoma, and to find out whether this best combination is better than standard CHOP treatment alone. The main questions this study will try to answer are: What percentage of participants will respond well to treatment with BEBT-908 plus CHOP? Is BEBT-908 plus CHOP better than standard CHOP treatment? What medical problems will participants have while receiving this combination treatment? This study includes an Exploration Phase and an Expansion Phase. The Exploration Phase has 3 cohorts. All participants receive both BEBT-908 and CHOP, but the dosing arrangements differ across cohorts: the dose of BEBT-908 differs, the sequencing of administration differs, and whether participants continue with CHOP or transition to BEBT-908 depends on their tolerability to CHOP. Eligible participants will receive the combination treatment for their assigned cohort. After that, based on the results from all 3 cohorts in the Exploration Phase, one optimal cohort will be selected to proceed into the Expansion Phase. In the Expansion Phase, eligible participants will be randomly assigned (like flipping a coin) in a 1:1 ratio to either the treatment group, receiving the optimal combination regimen identified in the Exploration Phase, or the control group, receiving 6 cycles of CHOP. This study design will help investigators find the best way to combine BEBT-908 and CHOP for treating previously untreated peripheral T-cell lymphoma, and check whether this optimal combination regimen is better than standard CHOP treatment.

Conditions

  • Previously Untreated Peripheral T-Cell Lymphoma

Interventions

  • Ifupinostat Hydrochloride for InjectionDrug

    Administered by intravenous infusion at a dose of 8.2 mg/m² or 18.5 mg/m². It is administered on days 1, 3, 5, 8, 10, and 12 of each cycle. Each cycle lasts 21 days.

  • Cyclophosphamide for InjectionDrug

    Administered by intravenous infusion at a dose of 750 mg/m². It is administered on day 1 of each cycle. Each cycle lasts 21 days.

  • Doxorubicin Hydrochloride for InjectionDrug

    Administered by intravenous infusion at a dose of 50 mg/m². It is administered on day 1 of each cycle. Each cycle lasts 21 days.

  • Vincristine Sulfate for InjectionDrug

    Administered by intravenous infusion at a dose of 1.4 mg/m² (maximum dose of 2 mg). It is administered on day 1 of each cycle. Each cycle lasts 21 days.

  • Prednisone Acetate TabletsDrug

    Administered by mouth at a dose of 100 mg. It is administered on days 1 through 5 of each cycle. Each cycle lasts 21 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: Up to 24 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.